Business & Regulation

Business & Regulation Business Practice

The Trump Effect on Cell and Gene: Science versus Shockwaves

04/01/2025 | 9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

Business & Regulation Standards & Regulation

Peter Marks Resigns from FDA

04/01/2025 | Stephanie Vine | 3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr.

Business & Regulation Standards & Regulation

Vaccines and Autism: Perpetuating a Populist Agenda

04/01/2025 | Rob Coker | 3 min read

Rumours claim that a well-known vaccine skeptic has been appointed to lead study on links between vaccines and autism.

Business & Regulation Digital Technologies

AI, Big Data, and Digital Disruption

03/31/2025 | Rob Ellison | 7 min read

An industry survey looks at changing attitudes and challenges in digital innovation for clinical research. Uptake is slow but steady.

Business & Regulation Standards & Regulation

The Future of the NIH

03/27/2025 | Hernan Bazan | 2 min read

Thoughts on the US National Institutes of Health and its role in funding research for non-opioid therapeutics.

Business & Regulation Business Practice

Calling Out Misleading Information

03/24/2025 | Rob Coker | 2 min read

FDA letter sent to Edenbridge Pharmaceuticals demonstrates the challenges of getting pharma advertising right.

Business & Regulation Advanced Medicine

We Need to Talk About CRISPR

03/21/2025 | 4 min read

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

Business & Regulation Digital Technologies

Forecasting Medicine Use and Controlling Supply Chains

03/19/2025 | Tim Tinnel | 3 min read

The role of digital technologies in optimizing traceability in pharmaceutical supply chains.

Business & Regulation Standards & Regulation

GSK’s Flovent Strategy Under Federal Scrutiny?

03/19/2025 | Rob Coker | 2 min read

US Senator Elizabeth Warren calls for a federal investigation into GSK and its discontinuation of Flovent HFA

Business & Regulation Trends & Forecasts

Drugs to Watch in 2025: Part 2

03/10/2025 | Stephanie Vine | 9 min read

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

Business & Regulation Business Practice

Biden’s Legacy; Trump’s Agenda: Part 2

03/07/2025 | 7 min read

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

Business & Regulation Trends & Forecasts

Drugs to Watch in 2025: Part 1

03/07/2025 | Stephanie Vine | 8 min read

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

Business & Regulation Supply Chain

The UK's Radiopharma Revolution

03/05/2025 | Juliana Maynard | 6 min read

Radiopharmaceuticals are a promising approach to cancer, but some countries are lagging behind. A collaboration hopes to change that.